Últimos 30 registros
Abaixo os últimos 30 registros encontrados em nossa base de dados.
Digite um termo acima para filtrar sua busca na tabela abaixo.
| Candidato | Patrocínio | Fase de testes | Instituição | Data |
|---|---|---|---|---|
| Moderna COVID‑19 Vaccine (mRNA-1273). APROVADA - Andorra, Brazil, Canada, European Union, Faroe Islands, Greenland, Guatemala, Honduras, Iceland, India, Israel, Japan, Liechtenstein, Moldova, Mongolia, Norway, Palestine, Philippines, Qatar, Saint Vincent and the Grenadines, Singapore, South Korea, Switzerland, Taiwan, Thailand, United Kingdom, United States, Vietnam, WHO | Moderna | Phase 3 | Kaiser Permanente Washington Health Research Institute | 2021/03/11 |
| EpiVacCorona - APROVADA (Russia, Turkmenistan) | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology | Peptide vaccine | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology | 2021/03/11 |
| No name announced. APROVADA - China | Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm) | PHASE-3 - Inactivated vaccine | Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm) | 2021/03/11 |
| COVID-19 Vaccine AstraZeneca (AZD1222); also known as Covishield - APROVADA -Argentina, Bahrain, Bangladesh, Barbados, Brazil, Canada, Chile, Dominican Republic, Ecuador, El Salvador, Egypt, EU, Guyana, Hungary, India, Iraq, Malaysia, Maldives, Mauritius, Mexico, Morocco, Myanmar, Nepal, Nigeria, Pakistan, Philippines, Saint Vincent and the Grenadines, South Africa, South Korea, Sri Lanka, Taiwan, Thailand, UK, Vietnam | BARDA, OWS | PHASE 3 - AUTHORIZATION / APPROVAL. Afghanistan, Albania, Algeria, Andorra, Angola, Argentina, Australia, Bahamas, Bahrain, Bangladesh, Barbados, Bhutan, Bolivia, Botswana, Brazil, Brunei, Cabo Verde, Cambodia, Canada, Cambodia, Caribbean, Chile, Colombia, Congo, Costa Rica, Djibouti, Dominican Republic, Ecuador, El Salvador, Egypt, Eswatani, Ethiopia, European Union, Faroe Islands, Fiji, Gambia, Georgia, Ghana, Greenland, Guatemala, Guinea-Bissau, Guyana, Honduras, Hungary (SII), Iceland, India, Indonesia, Iran, Iraq, Ivory Coast, Japan, Jordan, Kenya, Kosovo, Kuwait, Lebanon, Lesotho, Liberia, Libya, Malawi, Malaysia, Maldives, Mali, Mauritius, Mexico, Moldova, Mongolia, Morocco, Myanmar, Namibia, Nepal, Nicaragua, Nigeria, North Macedonia, Norway, Oman, Pakistan, Palestine, Panama, Papua New Guinea, Peru, Philippines, Rwanda, Saint Vincent and the Grenadines, Samoa, Serbia, Seychelles, Sierra Leone, Somalia, South Korea, South Sudan, Sri Lanka, Sudan, Suriname, Taiwan, Tajikistan, Thailand, Timor Leste, Tonga, Togo, Tuvalu, Uganda, Ukraine, UK, Uzbekistan, Vietnam, WHO (Oxford; SII/SK), Yemen, Zambia | AstraZeneca - UK | 2021/03/11 |
| JNJ-78436735 (formerly Ad26.COV2.S). APROVADA - Bahrain, Saint Vincent and the Grenadines, US | Janssen Vaccines (Johnson & Johnson) | PHASE 3 - Non-replicating viral vector | (Johnson & Johnson) / The Netherlands, US | 2021/03/11 |
| Convidicea (Ad5-nCoV) / APROVADA (Mexico, China, Pakistan) | CanSino Biologics | PHASE -3 - Recombinant vaccine (adenovirus type 5 vector) | CanSino Biologics - CHINA | 2021/03/11 |
| CoviVac - Aprovada - Rússia | Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products | Inactivated vaccine | Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products = Rússia | 2021/03/11 |
| ZF2001 - APROVADA - Uzbekistan | Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences | Recombinant vaccine | China, Uzbekistan | 2021/03/11 |
| Abdala (CIGB 66) | Center for Genetic Engineering and Biotechnology | Phase 3 | Center for Genetic Engineering and Biotechnology | 2021/03/11 |
| VIR-7831 | Medicago; GSK; Dynavax | Phase 2/3 | Medicago | 2021/03/11 |
| No name announced | ImmunityBio; NantKwest | Phase 2/3 - Adenovirus-based vaccine | 2021/03/11 | |
| UB-612 | COVAXX | Phase 2/3 - Multitope peptide-based vaccine | United Biomedical Inc. (UBI) | 2021/03/11 |
| No name announced | Sanofi; GlaxoSmithKline | Recombinant protein vaccine - Phase 2 | Various | 2021/03/11 |
| BNT162 | Pfizer, BioNTech | Phase 1/2/3 | Multiple study sites in Europe, North America and China | 2021/03/11 |
| Soberana 1 and 2 | Finlay Institute of Vaccines | Phase 1/2/3 | Finlay Institute of Vaccines | 2021/03/11 |
| AdCLD-CoV19 | Cellid; LG Chem | Phase 1/2a | Korea University Guro Hospital | 2021/03/11 |
| Nanocovax | Nanogen Biopharmaceutical | Phase 1/2 - Recombinant vaccine (Spike protein) | Military Medical Academy (Vietnam) | 2021/03/11 |
| EuCorVac-19 | EuBiologics | Phase 1/2 - nanoparticle vaccine | Eunpyeong St. Mary’s Hospital | 2021/03/11 |
| Mambisa (CIGB 669) | Center for Genetic Engineering and Biotechnology | Phase 1/2 - Protein subunit vaccine | Center for Genetic Engineering and Biotechnology | 2021/03/11 |
| IIBR-100 | Israel Institute for Biological Research | Phase 1/2 - Recombinant vesicular stomatitis virus (rVSV) vaccine | Hadassah Medical Center; Sheba Medical Center Hospital | 2021/03/11 |
| No name announced | West China Hospital, Sichuan University | Phase 1/2 - SF9 cell vaccine candidate | West China Hospital, Sichuan University | 2021/03/11 |
| VLA2001 | Valneva; National Institute for Health Research (NIHR) | Phase 1/2 - Inactivated vaccine | Multiple NIHR testing sites | 2021/03/11 |
| No name announced | CEPI | Phase 1/2 - Adjuvanted protein subunit vaccine | 2021/03/11 | |
| ARCT-021 (LUNAR-COV19) | Arcturus Therapeutics and Duke-NUS Medical School | Phase 1/2 - Self-replicating RNA vaccine | Duke-NUS Medical School, Singapore | 2021/03/11 |
| No name announced | Chinese Academy of Medical Sciences, Institute of Medical Biology | Phase 1/2 - Inactivated vaccine | West China Second University Hospital, Yunnan Center for Disease Control and Prevention | 2021/03/11 |
| AV-COVID-19 | Aivita Biomedical, Inc. | Phase 1b/2 - Dendritic cell vaccine | Rumah Sakit Umum Pusat Dr Kariadi | 2021/03/11 |
| PTX-COVID19-B | Providence Therapeutics; Canadian government | Phase 1 - mRNA-based vaccine | 2021/03/11 | |
| COVI-VAC | Codagenix; Serum Institute of India | Phase 1 - Intranasal vaccine | 2021/03/11 | |
| CORVax12 | OncoSec; Providence Cancer Institute | Phase 1 - DNA vaccine (plasmid) | Providence Portland Medical Center | 2021/03/11 |
| MVA-SARS-2-S | Universitätsklinikum Hamburg-Eppendorf; German Center for Infection Research; Philipps University Marburg Medical Center; Ludwig-Maximilians - University of Munich | Phase 1 - Modified vaccinia virus ankara (MVA) vector vaccine candidate | University Medical Center Hamburg-Eppendorf | 2021/03/11 |
